Cogent Biosciences, Inc.
COGT
$37.93
$0.621.66%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 137.89% | 137.25% | 104.76% | 21.75% | 32.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.80% | 38.27% | 34.94% | 10.53% | 17.39% |
| Operating Income | -35.80% | -38.27% | -34.94% | -10.53% | -17.39% |
| Income Before Tax | -31.11% | -35.24% | -50.89% | -14.58% | -24.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.11% | -35.24% | -50.89% | -14.58% | -24.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.11% | -35.24% | -50.89% | -14.58% | -24.73% |
| EBIT | -35.80% | -38.27% | -34.94% | -10.53% | -17.39% |
| EBITDA | -36.00% | -38.61% | -35.23% | -10.59% | -17.48% |
| EPS Basic | 12.20% | 5.50% | -11.79% | 8.23% | -8.06% |
| Normalized Basic EPS | 12.19% | 5.49% | -11.17% | 8.22% | -8.05% |
| EPS Diluted | 12.20% | 5.50% | -11.79% | 8.23% | -8.06% |
| Normalized Diluted EPS | 12.19% | 5.49% | -11.17% | 8.22% | -8.05% |
| Average Basic Shares Outstanding | 49.34% | 43.11% | 34.97% | 24.83% | 15.42% |
| Average Diluted Shares Outstanding | 49.34% | 43.11% | 34.97% | 24.83% | 15.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |